Clostridium difficile infections among Jordanian adult hospitalized patients

American Journal of Infection Control

Volumn 37, Issue 10, 2009, Pages 864-866

  Nasereddin, Lina M ^a   Bakri, Fares G ^b   Shehabi, Asem A ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

^b JORDAN UNIVERSITY HOSPITAL   (Jordan)

Author keywords

antibiotic resistance; Clostridium difficile infection; Jordanian patients; toxin genes

Indexed keywords

CIPROFLOXACIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; LEVOFLOXACIN; METRONIDAZOLE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; EARLY DIAGNOSIS; FECES CULTURE; FEMALE; HOSPITAL PATIENT; HUMAN; INFECTION PREVENTION; JORDAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIOLOGICAL TECHNIQUES; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FECES; FEMALE; FLUOROQUINOLONES; HOSPITALS; HUMANS; JORDAN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES;

EID: 71249108263     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2009.05.001     Document Type: Article

References (14)

1. Kuijper E.J., Coignard B., and Tull P. ESCMID Study Group for Clostridium difficile; EU Member States; and European Centre for Disease Prevention and Control (ECDC). Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12 (2006) 2-18
2. McDonald L.C., Owings M., and Jernigan D.B. Increasing rates of Clostridium difficile infection among patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12 (2006) 409-415
3. Poxton R.I. Clostridium difficile. J Med Microbiol 57 (2008) 750-756
4. Spigaglia P., Barbanti F., Mastrantonio P., Brazier J.S., Barbut F., Delmée M., et al. European Study Group on Clostridium difficile (ESGCD). Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C difficile infections in Europe. J Med Microbiol 57 (2008) 784-789
5. Pépin J., Alary M.-E., Valiquette L., Raiche E., Ruel J., Fulop K., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41 (2005) 1254-1260
6. van der Kooi T.I., Koningstein M., Lindemans A., Notermans D.W., Kuijper E., van den Berg R., et al. Antibiotic use and other risk factors at hospital level for outbreaks with Clostridium difficile PCR ribotype 027. J Med Microbiol 57 (2008) 709-716
7. McDonald L.C., Killgore G.E., and Thompson A. An epidemic, toxin gene variant strain of Clostridium difficile. N Engl J Med 353 (2005) 2433-2441
8. Barbut F., Mastrantonio P., Delmee M., Brazier J., Kuijper E., and Poxton I. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 13 (2007) 1048-1057
9. Shehabi A., Abu-Ragheb H., and Allaham N. Prevalence of Clostridium difficile-associated diarrhea among hospitalized patients. East Mediterr Health J 7 (2004) 750-755
10. Pinto L.J.F., Alcides A.P.P., Ferreira E.O., Avelar K.E.S., Sabrá A., Domingues R.M.C.P., et al. Incidence and importance of Clostridium difficile in paediatric diarrhoea in Brazil. J Med Microbiol 52 (2003) 1095-1099
11. CLSI. Methods for antimicrobial susceptibility testing of anaerobic bacteria, approved standard. 7th edition (2007), CLSI, Wayne, PA CLSI document M11-A7
12. Terhes G., Urbán E., Sóki J., Hamid K.H., and Nagy E. Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol 42 (2004) 4316-4318
13. Dridi L., Tankovic J., Burghoffer B., Barbut F., and Petit J. C gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 46 (2002) 3418-3421
14. Norén T., Wullt M., Åkerlund T., Bäck I., Odenholt I., and Burman L.G. Frequent emergence of resistance in Clostridium difficile during treatment of C difficile-associated diarrhea with fusidic acid. J Antimicrob Chemother 50 (2006) 3028-3032